Putin, Trump and Volodymyr Zelenskyy
Digest more
Vladimir Putin gave Donald Trump a strict 15-minute window to make a late-night phone call to the Kremlin after White House peace talks with Ukraine’s Volodymyr Zelensky.
US President Donald Trump has stated that on 18 August, he did not speak with Russian leader Vladimir Putin in the presence of European leaders, as this would have been disrespectful to the Kremlin head.
12hon MSN
Ukraine wants a ‘ceasefire,’ Putin and Trump want a ‘peace deal.’ Here’s the big difference
US President Donald Trump has ditched his call for a ceasefire in Ukraine, backing instead Russian President Vladimir Putin’s push for a permanent peace agreement. That has not stopped some European leaders from pushing for a temporary truce first, even though the US president has seemingly decided one is not necessary.
The French president was among the European leaders who visited the White House to present a united front in support of Ukraine.
19hon MSN
Bessent: Trump Inviting Putin To Alaska Was Like Showing Your Out-Of-Control Neighbor Your Gun Case
Treasury Secretary Scott Bessent delivered this line in response to criticism of President Trump inviting Russian President Vladimir Putin to U.S. territory: "He displayed a huge amount of military hardware and then did a flyover.
Donald Trump displayed a stunning ignorance of the Cold War during last week’s summit with Russian President Vladimir Putin, according to his biographer. Author Michael Wolff told the Daily Beast podcast Inside Trump’s Head on Tuesday that,
US President Donald Trump was reportedly ready to cut short talks with Kremlin leader Vladimir Putin in Alaska due to Putin's intransigence over his demand to annex the entire Donetsk Oblast. Source: Axios,
20hon MSN
Trump wants a Zelenskyy-Putin meeting and Hurricane Erin threatens North Carolina: Morning Rundown
Trump meets with Ukraine’s Zelenskyy and other European leaders at the White House. Hurricane Erin forecast to bring life-threatening surf and rip currents to East Coast. And promising medication for children with an ultra-rare and often fatal disease faces a major FDA setback.